Is there still a place for vinorelbine in advanced metastatic castration resistant prostate cancer?

Giandomenico Roviello, Silvia Paola Corona, Raffaele Conca, Roberto Petrioli, Pietro Rosellini, Alberto Bonetta, Michele Aieta

Research output: Contribution to journalArticle


The aim of this paper was to evaluate the activity and tolerability of oral vinorelbine in patients with advanced castration resistant prostate cancer (CRPC) who progressed after a minimum of three lines including: abiraterone acetate, docetaxel, cabazitaxel, and enzalutamide.Treatment consisted of weekly oral vinorelbine 60 mg/m. Chemotherapy was administered until disease progression or unacceptable toxicity.Twenty-six patients received vinorelbine: their median age was 74 years (range 58-84 years). Twenty-four (92.3%) patients had bone metastases. A decrease in PSA levels ≥50% was observed in 2 patients (7.7%). Among the subjects who were symptomatic at baseline, pain was reduced in 3 patients (13.6%) with a significant decrease in analgesic use. Median progression-free survival was 9 weeks (95% CI: 7 to 11) and median overall survival was 17 weeks (95% CI: 12 to 22). Treatment was well tolerated, and no grade 4 toxicities were observed.Our findings do not suggest the use of oral vinorelbine on a weekly schedule, in CRPC heavily pre-treated.

Original languageEnglish
Pages (from-to)e16249
Issue number26
Publication statusPublished - Jun 1 2019


ASJC Scopus subject areas

  • Medicine(all)

Cite this